ATE445637T1 - Synthese von peptid t-20 mit peptidfragmentzwischenprodukten - Google Patents

Synthese von peptid t-20 mit peptidfragmentzwischenprodukten

Info

Publication number
ATE445637T1
ATE445637T1 AT05823175T AT05823175T ATE445637T1 AT E445637 T1 ATE445637 T1 AT E445637T1 AT 05823175 T AT05823175 T AT 05823175T AT 05823175 T AT05823175 T AT 05823175T AT E445637 T1 ATE445637 T1 AT E445637T1
Authority
AT
Austria
Prior art keywords
peptide
synthesis
intermediate products
fragment intermediate
peptide fragment
Prior art date
Application number
AT05823175T
Other languages
English (en)
Inventor
Yeun-Kwei Han
David Johnston
Hiralal Khatri
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Application granted granted Critical
Publication of ATE445637T1 publication Critical patent/ATE445637T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus human T-cell leukaemia-lymphoma virus
    • C07K14/155—Lentiviridae, e.g. human immunodeficiency virus [HIV], visna-maedi virus or equine infectious anaemia virus
    • C07K14/16—HIV-1 ; HIV-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • AIDS & HIV (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Peptides Or Proteins (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT05823175T 2004-12-30 2005-12-22 Synthese von peptid t-20 mit peptidfragmentzwischenprodukten ATE445637T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US64082204P 2004-12-30 2004-12-30
PCT/EP2005/013852 WO2006069727A2 (en) 2004-12-30 2005-12-22 Synthesis of peptide t-20 using peptide intermediate fragments

Publications (1)

Publication Number Publication Date
ATE445637T1 true ATE445637T1 (de) 2009-10-15

Family

ID=36520126

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05823175T ATE445637T1 (de) 2004-12-30 2005-12-22 Synthese von peptid t-20 mit peptidfragmentzwischenprodukten

Country Status (12)

Country Link
US (1) US20070213504A1 (de)
EP (1) EP1960423B1 (de)
JP (1) JP4886701B2 (de)
KR (1) KR20070111463A (de)
CN (1) CN101133078B (de)
AT (1) ATE445637T1 (de)
CA (1) CA2593864C (de)
DE (1) DE602005017206D1 (de)
ES (1) ES2332142T3 (de)
IL (1) IL184081A (de)
MX (1) MX2007007916A (de)
WO (1) WO2006069727A2 (de)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2205624B1 (de) * 2007-10-27 2016-09-07 Corden Pharma Colorado, Inc. Synthese eines insulinotropen peptids mithilfe von feststoff- und flüssigphasenkombinationsverfahren
MX2010006044A (es) * 2007-12-11 2010-06-23 Hoffmann La Roche Sintesis de peptidos insulinotropicos utilizando una combinacion de tecnicas en fase solida y en solucion.
CN102680463B (zh) * 2012-05-17 2014-07-02 新疆天康畜牧生物技术股份有限公司 一种改进的茚三酮对固相多肽合成的检测方法
CN110372781B (zh) * 2019-07-29 2021-11-16 深圳佳肽生物科技有限公司 恩夫韦肽的制备方法和应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5817758A (en) * 1995-06-07 1998-10-06 Terrapin Technologies, Inc. P-nitrobenzyl side-chain protection for solid-phase synthesis
US6281331B1 (en) * 1998-03-23 2001-08-28 Trimeris, Inc. Methods and compositions for peptide synthesis
US20040209999A1 (en) * 2002-08-16 2004-10-21 Bohling James Charles Method of manufacturing polypeptides, including T-20 and T-1249, at commercial scale, and polypeptide compositions related thereto
AU2004200485A1 (en) * 2003-02-25 2004-09-09 Rohm And Haas Company Method of manufacturing T-20 and T-1249 peptides at commercial scale, and T-20 and T-1249 compositions related thereto

Also Published As

Publication number Publication date
CA2593864A1 (en) 2006-07-06
WO2006069727A2 (en) 2006-07-06
IL184081A0 (en) 2007-10-31
ES2332142T3 (es) 2010-01-27
JP2008526697A (ja) 2008-07-24
CN101133078B (zh) 2011-07-27
MX2007007916A (es) 2007-08-14
IL184081A (en) 2010-12-30
EP1960423B1 (de) 2009-10-14
WO2006069727A3 (en) 2006-08-10
DE602005017206D1 (de) 2009-11-26
CA2593864C (en) 2013-08-06
EP1960423A2 (de) 2008-08-27
KR20070111463A (ko) 2007-11-21
JP4886701B2 (ja) 2012-02-29
CN101133078A (zh) 2008-02-27
US20070213504A1 (en) 2007-09-13

Similar Documents

Publication Publication Date Title
ES2533874T3 (es) Armazón proteico
DE602005008996D1 (de) Radiofluorierte peptide
ATE507235T1 (de) Synthese von glucagon-ähnlichen peptiden
WO2006027705A3 (en) Synthesis of triethylenetetramines
IL206497A (en) Isolated nucleic acid encoding the carboxylic end of a conxin protein bound to a cellular carrier
DK1511761T3 (da) Fremgangsmåde til fremstilling af cykliske peptider
AR076977A1 (es) Proteinas precursoras repetitivas autoensambladas
ATE538199T1 (de) Ribosomenpräsentations- und mrna- präsentationsverfahren mit selektion hinsichtlich erhöhter stabilität des proteins
CL2008003660A1 (es) Metodo para obtener un peptido insulinotropico tipo glp-1 mediante la union de fragmentos del mismo ya sea en solucion o en fase solida; y peptidos intermediarios aqui empleados.
ATE425179T1 (de) Reinigung von glykopeptiden
BRPI0718996A2 (pt) Síntese de peptídio em fase sólida com boc e fmoc.
ATE445637T1 (de) Synthese von peptid t-20 mit peptidfragmentzwischenprodukten
IL184080A (en) Synthesis of peptide t-20 using peptide intermediate fragments
MX2007013400A (es) Metodo de sintesis de peptidos.
ATE439371T1 (de) Synthese von peptid t-1249 mit peptidzwischenproduktfragmenten
WO2007078633A8 (en) Bacteriocin inducer peptides
ATE466874T1 (de) Mit scytovirin der domäne 1 verwandte polypeptide
MX2010003179A (es) Metodos de sintesis para peptidos anti-vih terapeuticos.
EA201291416A1 (ru) Пептиды, связывающиеся с рецептором инсулиноподобного фактора роста 1
ATE512159T1 (de) Cyclodipeptidsynthetasen und ihre verwendung zur synthese von cyclo(leu-leu)cyclodipeptid
DK1480998T3 (da) Mellemprodukter og fremgangsmåder til fremstilling af heptapeptidoxytocinanaloger
ATE448240T1 (de) Peptidsynthese von alpha-helices auf peg-harz
ATE422366T1 (de) Verwendung von mischungen von lipopeptiden zur bereitung von impfstoffen
ATE381572T1 (de) Synthese von spongosin
ATE338767T1 (de) Dipeptidische wachstumshormonsekretionsförderern

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties